Small Business Innovation Research (SBIR) to Develop New or Improved Closed Loop Automated Technologies for Diabetes Therapy and Monitoring (R43/R44)
The summary for the Small Business Innovation Research (SBIR) to Develop New or Improved Closed Loop Automated Technologies for Diabetes Therapy and Monitoring (R43/R44) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Small Business Innovation Research (SBIR) to Develop New or Improved Closed Loop Automated Technologies for Diabetes Therapy and Monitoring (R43/R44): This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of innovative technologies that may advance progress toward integrated long term glucose regulated insulin/pancreatic hormones automated delivery systems (artificial pancreas).
Federal Grant Title: | Small Business Innovation Research (SBIR) to Develop New or Improved Closed Loop Automated Technologies for Diabetes Therapy and Monitoring (R43/R44) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-15-022 |
Type of Funding: | Grant |
CFDA Numbers: | 93.847 |
CFDA Descriptions: | Diabetes, Digestive, and Kidney Diseases Extramural Research |
Current Application Deadline: | Nov 18, 2015 |
Original Application Deadline: | Nov 18, 2015 |
Posted Date: | Jul 24, 2015 |
Creation Date: | Jul 24, 2015 |
Archive Date: | Dec 19, 2015 |
Total Program Funding: | $2,500,000 |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. - Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-022.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial...
- • Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial...
- • Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortiu...
- • Diabetes Research Centers (P30 Clinical Trial Optional)
- • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...
- • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
- • Molecular Therapy Core Centers
- • Pilot and Feasibility Program in Human Islet Biology
- More Grants from the National Institutes of Health
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...